PT  - JOURNAL ARTICLE
AU  - Jacob B. Aguilar
AU  - Jeremy Samuel Faust
AU  - Lauren M. Westafer
AU  - Juan B. Gutierrez
TI  - Modeling the Impact of Asymptomatic Carriers on COVID-19 Transmission Dynamics During Lockdown
AID  - 10.1101/2020.03.18.20037994
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.03.18.20037994
4099  - http://medrxiv.org/content/early/2020/08/11/2020.03.18.20037994.short
4100  - http://medrxiv.org/content/early/2020/08/11/2020.03.18.20037994.full
AB  - Coronavirus disease 2019 (COVID-19) is a novel human respiratory disease caused by the SARS-CoV-2 virus. Asymptomatic carriers of the COVID-19 virus display no clinical symptoms but are known to be contagious. Recent evidence reveals that this sub-population, as well as persons with mild disease, are a major contributor in the propagation of the disease. The fast spread of COVID-19 forced governments around the world to establish and enforce generalized lockdowns, geared towards minimizing community transmission. This created an unprecedented epidemiological situation not properly characterized by existing mathematical models of isolation and quarantine. In this manuscript, we present a mathematical model for community transmission of COVID-19 taking into account asymptomatic carriers during the lockdown period. The main results consist of an exact calculation of the effective reproduction number , and a modeling framework that enables the quantification of generalized lockdowns on community transmission. A computation of is provided, assuming mean parameters. The first three weeks of the model exhibit exponential growth, which is in agreement with average case data collected from thirteen countries with universal health care and robust communicable disease surveillance systems. The point estimate of the basic reproduction number is .Competing Interest StatementThe authors have declared no competing interest.Funding StatementN/AAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this article is available from public sources. https://mathresearch.utsa.edu/wp/?p=58